United Therapeutics (NASDAQ: UTHR) received a number of price target changes and ratings updates during the last week:
- United Therapeutics was downgraded by analysts at Brean Murray from a “buy” rating to a “hold” rating.
- United Therapeutics had its price target raised by analysts at RBC Capital from $45.00 to $50.00. They now have a “sector perform” rating on the stock.
- United Therapeutics had its price target raised by analysts at Canaccord Genuity from $44.00 to $54.00. They now have a “hold” rating on the stock.
- United Therapeutics had its price target raised by analysts at Jefferies Group from $45.00 to $52.00. They now have a “hold” rating on the stock.
- United Therapeutics had its “hold” rating reaffirmed by analysts at Deutsche Bank. They now have a $56.00 price target on the stock, up previously from $52.00. They wrote, “We are raising our TP to $56 from $52 current. Maintain HOLD. We are raising our TP to $56 as we cut our expense numbers in out years to keep them in-line with significant sales erosion beginning 2017 & since we are not modeling Oral Remodulin sales. We continue to remain on sidelines as we seek more clarity on 1) Commercial OPP’Y for Oral Remodulin and 2) Patent issues with Sandoz.”
United Therapeutics opened at 61.405 on Wednesday. United Therapeutics has a 1-year low of $40.34 and a 1-year high of $61.54. The stock’s 50-day moving average is currently $55.22. The company has a market cap of $3.081 billion and a price-to-earnings ratio of 10.75.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.